Clinical Trial Update: A Single Agent Study to Evaluate the Overall Response Rate, Safety and Tolerability of Orally Administered Vemurafenib [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 single-agent trial of vemurafenib in multiple myeloma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Vemurafenib (vemurafenib)

Snippet

Sponsor: University of Arkansas | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: WITHDRAWN